Zantac and ranitidine are routinely used by millions of heartburn sufferers. So how did the drug become a cancer risk?

Delaware's highest court ruled on Thursday that nearly 75,000 patients suing four large drugmakers cannot introduce reports ...

Two drugmakers initiated recalls of generic versions of Zantac after testing found a probable carcinogen.

Aurobindo Pharma USA, Inc. is the latest company to issue a voluntary recall of ranitidine products over concerns regarding "probable" carcinogen NDMA.

There are now nearly a dozen recalls for the generic version of Zantac since late September for a potential cancer-causing impurity.

Zantac and ranitidine have made a lot of headlines recently, after the FDA made the decision to investigate possible contaminants in ranitidine products.

CONSUMER CATCH-UP: Zantac and other drugs are being pulled by manufacturers for possible carcinogen, find out what to do if your car is recalled during novel coronavirus, and retailers are seeing ...

More prescription-strength and hospital-used ranitidine, sold over the counter under the brand name Zantac, has been recalled for having too much of carcinogen NDMA. Though the run of recalls on ...

The FDA has requested all ranitidine (Zantac) products be pulled from the market immediately. The recall includes all prescription and over-the-counter ranitidine drugs as ongoing investigations ...

A voluntary recall of a generic version of Zantac has been issued because the drug has been found to contain a contaminant that could cause cancer. Sandoz Inc. is recalling 14 lots of prescription ...

Lab investigates heartburn drug’s possible cancer link Washington — U.S. health regulators are telling drugmakers to immediately pull their popular heartburn drugs off the market after ...

Another recall has been issued for a generic version of a popular heartburn drug best known as Zantac due to the presence of a potentially cancer-causing impurity. It's the latest in several such ...